Global Ankylosing Spondylitis Market Overview:

The report spread across 50 pages is an overview of the Global Ankylosing Spondylitis Market Report 2019. The Global Ankylosing Spondylitis Market is projected to grow at a healthy growth rate from 2019 to 2023 according to new research. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.

This report studies the Global Ankylosing Spondylitis Market over the forecast period of 2019 to 2023. The Global Ankylosing Spondylitis Market is expected to grow at an impressive Compound Annual Growth Rate (CAGR) from 2019 to 2023.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/162940 .

According to the market report analysis, Ankylosing Spondylitis is a chronic inflammatory disease that affects the spine. It is a type of arthritis, in which spine bones grow or fuse together, causing the spine to become rigid. Basically, Ankylosing Spondylitis causes pain in spine but in some cases Ankylosing Spondylitis can cause swelling and pain in heels, chest, hips and shoulders. Early diagnosis is crucial in Ankylosing Spondylitis as spinal deformity can be minimized with the help of proper treatment.

In terms of the geographic analysis, North America dominates the global market for Ankylosing Spondylitis. Additionally, technological advancements are driving Ankylosing Spondylitis in North America. APAC, followed by Europe, is expected to experience high growth rate in the Ankylosing Spondylitis Market over the next few years. China and India are expected to be the fastest-growing Ankylosing Spondylitis Markets in the APAC region.

Top Leading Key Players in Global Ankylosing Spondylitis Market: AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, and Merck & Co. Inc and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Current Business News:

1 AbbVie (June 04, 2019) – AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months in previously untreated patients with CLL and coexisting medical conditions. The results demonstrate that venetoclax plus obinutuzumab prolonged progression-free survival (PFS) and achieved higher rates of complete response and minimal residual disease (MRD)-negativity compared to a commonly used standard of care obinutuzumab plus chlorambucil.1

"Conducting CLL14 was another collaborative and bold attempt to continue pushing the boundaries of treatment in CLL," said Mohamed Zaki, M.D., Ph.D., vice president, global head of hematology development, AbbVie. "The combination of venetoclax plus obinutuzumab significantly prolonged progression-free survival and patients maintained that benefit after stopping treatment. After the recent approval in the U.S., we look forward to continue working with health authorities worldwide as we aim to bring venetoclax plus obinutuzumab to patients with previously untreated CLL."

2 Pfizer (April 26, 2019) – Pfizer Receives Positive Chmp Opinion for Talzenna (Talazoparib) for Patients with Inherited (Germline) Brca-mutated Locally Advanced or Metastatic Breast Cancer – Pfizer Inc., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, be granted marketing authorization in the European Union (EU). The indication the CHMP adopted is for TALZENNA as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC). Patients should have been previously treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive (HR+) breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.

“There is a pressing need for new, effective medicines that are specifically developed for patients with an inherited BRCA mutation who are often diagnosed at a younger age and have limited options for the treatment of advanced-stage disease,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “Results from the EMBRACA trial provide evidence supporting the use of TALZENNA in these patients, and we look forward to working with the European Commission to potentially offer an alternative treatment option to chemotherapy.”

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Ankylosing Spondylitis in these regions, from 2013 to 2023 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Purchase this report online with 50 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Ankylosing Spondylitis Market Report 2019” @ https://www.businessindustryreports.com/buy-now/162940/single .

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

[email protected]

+19376349940